Advanced lung cancer is difficult to treat since it engulfs other lobes of the lungs and even other organs of the body. Surgical resection does not work in such situations. Doctors usually go with chemotherapy and radiotherapy to treat such patients. However, there are many patients who can’t go through chemotherapy; the side effects are too many. A new treatment for lung cancer is taking shape, and it is called immunotherapy lung cancer. The aim of this kind of treatment is to strengthen the immune system and release it from the devious cancer cells. This bolsters the immune system to fight the cancer cells.
Immunotherapy lung cancer
Immune checkpoints
The most important aspect of immunotherapy is the immune checkpoint. In this therapy, certain checkpoints in the immune system can be selectively disabled to work to the benefit of the cancer cells.
PD-1 checkpoint
The cancer cells take over the immune checkpoints so that the immune system is not able to target them. There are many such checkpoints in the immune system. The PD-1 checkpoint is one of these. With the help of lung cancer treatment immunotherapy, these checkpoints can be blocked. As the checkpoints are blocked, the immune system regains its insight, identifies the cancer cells and attacks them. The drugs to this effect are administered intravenously and do not necessitate hospitalization.
Only for non-small cell lung cancer
However, it must be said that this therapy is suitable only for non-small cell carcinoma lung cancer patients. It is not yet being used on patients suffering from small cell carcinoma.
Side effects
There are certain side effects of immunotherapy lung cancer, but those are fewer compared to chemotherapy. Most of the side effects involve allergic skin reactions. However, there may be other side effects too, such as inflammation of the lungs or the gut or even abnormalities with the endocrine system.
It does not work for everybody
However, immunotherapy does not work for everybody. It works in about 30% of patients suffering from advanced non-small cell lung cancer. Some patients with a lung tumor respond better to targeted therapy. It has been seen that targeted therapy in some patients with lung cancer can reduce the size of the tumor better than immunotherapy.
